{"Clinical Trial ID": "NCT02513472", "Intervention": ["INTERVENTION 1:", "Strata 1: Erebulin mesylate + Pembolizumab", "Participants who were never treated with systemic anticancer therapy in metastatic media received 1.4 mg/m^2, 1 intravenous infusion on days 1 and 8 and 200 mg pembrolizumab, 1 intravenous infusion on day 1 in treatment cycle 1 (safety screening, phase 1b) and then continued in each 21-day treatment cycle in the presence of clinical benefit until disease progression was confirmed, unacceptable toxicity development, participant request, withdrawal of consent or cessation of the sponsor's study in Phase 2 of Stratum 1.", "INTERVENTION 2:", "Stratum 2: Erebulin mesylate + Pembolizumab", "Participants who had previously received 1 to 2 systemic anticancer lines in metastatic media received 1.4 mg/m^2, 1 intravenous infusion on days 1 and 8 and 200 mg pembrolizumab, 1 intravenous infusion on day 1 in treatment cycle 1 (Safety Trial, Phase 1b) and then continued in each 21-day treatment cycle in the presence of clinical benefit until disease progression was confirmed, development of unacceptable toxicity, participant's request, withdrawal of consent or cessation of the sponsor's study in phase 2 of stratum 2."], "Eligibility": ["Incorporation criteria:", "Women or men >=18 years of age at the time of signing the Informed Consent Form (ICF).", "- MTNBC (confirmed from the most recent tissue sample) meeting the following criteria:", "Estrogen receptor (ER) and negative progesterone receptor (a tumour is ER and/or positive progesterone receptor if at least 1 percent (%) of the cells examined have estrogen and/or progesterone receptors) and human epidermal growth factor receptor 2 (HER2) negative (defined as immunohistochemistry [IHC] less than (<)2+ or negative in situ hybridization [FISH].", "- Hormonal treatment and bone metastases (e.g., bisphosphonates, denosumab, etc.) are not considered as systemic forms of cancer treatment.", "Presence of a measurable disease meeting the following criteria:", "At least 1 lesion of >=10 millimetre (mm) in the diameter of the long axis for non-lymphatic nodes or >=15 mm in the diameter of the short axis for lymph nodes which is measured in series according to the criteria for evaluating response in solid tumours version 1.1 (RECIST 1.1) using computerized tomography (CT) or magnetic resonance imaging (MRI) or panoramic and close-up colour photography.", "Injuries that have undergone radiation therapy must demonstrate subsequent X-ray evidence of an increased size to be considered a target injury.", "Life expectancy >=3 months.", "The Eastern Cooperative Oncology Group (ECOG) achieved a performance status (PS) of 0 or 1.", "adequate renal function, as demonstrated by serum creatinine less than or equal to (<=) 1.5 milligram per deciliter (mg/dL) or creatinine clearance calculated >=50 millimetre per minute (mL/min) in the Cockcroft and Gault formula.", "Adequate bone marrow function, defined as follows:", "Absolute number of neutrophils (ANC) >=1.5*10^9/L.", "Haemoglobin (Hb) >=10.0 gram per deciliter (g/dL) (may be corrected by growth factor or transfusion).", "Number of platelets >=100*10^9/L.", "Adequate liver function, defined as:", "Total bilirubin <=1.5*upper limit of normal (ULN).", "- Alcaline phosphatase (ALP), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3*ULN unless there are bone metastases, in which case the liver-specific alkaline phosphatase should be separated from the total and used to evaluate liver function instead of total alkaline phosphatase.", "\u2022 Resorption of all toxicities related to chemotherapy or radiotherapy to a severity or lower severity of grade 1, with the exception of stable sensory neuropathy (<= Grade 2) and alopecia.", "\u2022 Sample of archived tissue or new biopsy sample.", "Females should not be breast-feeding or pregnant for initial screening or screening (as indicated by a negative beta-human gonadotropin test [B-hCG] (or human chorionic gonadotropin [hCG]) with a minimum sensitivity of 25 international units per litre (IU/L) or equivalent units of B-hCG [or hCG]). A separate baseline assessment is required if a negative pregnancy test was obtained more than 72 hours prior to the first dose of the study drug.", "All women will be considered to be of childbearing age unless they are menopausal (amenorrheic for at least 12 consecutive months, in the appropriate age group and without any other known or suspected cause) or have been surgically sterilized (i.e. bilateral tubular ligature, total hysterectomy or bilateral oophorectomy, all with surgery at least one month prior to administration).", "Women who use hormonal contraceptives should have received a stable dose of the same hormonal contraceptive product for at least 28 days prior to administration and should continue to use the same contraceptive during the study and for 120 days after the drug has been discontinued.", "Men who have had a successful vasectomy (azoospermia confirmed) or who meet the above criteria with their female partners (i.e. who are not of childbearing age or who use very effective contraception throughout the study period or for 120 days after stopping the study drug).", "\u2022 Voluntary and able to comply with all aspects of the treatment protocol.", "\u2022 Provide written informed consent.", "- Exclusion criteria:", "A prior treatment with erebulin mesylate or any anti-programming-1 death receptor (anti-PD-1), a programmed ligand-1 death receptor (PD-L1) or a PD-L2 agent.", "In the last two years, an active autoimmune disease has required systemic treatment (i.e., the use of disease-modifying agents, corticosteroids or immunosuppresive medicines).", "Less than 6 months since previous adjuvant chemotherapy.", "The current listing in another interventional clinical study or the use of a drug or experimental device within the last 28 days prior to informed consent.", "Treatment with chemotherapy or biological therapy in the previous 3 weeks, targeted radiation treatment or small molecule in the previous 2 weeks.", "A known Central Nervous System (CNS) disease, except for participants with treated brain metastases who are stable for at least one month, have no signs of progression or hemorrhage after treatment and do not have permanent corticosteroid requirements, as demonstrated by clinical examination and brain imaging (MRI or CT) during the screening period.", "\u2022 Known history of positive human immunodeficiency virus (HIV).", "- Hepatitis B (example, reactive HBsAg) or hepatitis C (example, ribonucleic acid of the detected hepatitis C virus (HCV RNA).", "The current toxicity associated with the anticancer treatment of grades >= 2 (with the exception of alopecia and sensory neuropathy of grade 2) according to the common terminology criteria for adverse events (CTCAE v4.03).", "Any other disease requiring treatment or showing recurrence (with the exception of non-melanoma skin cancer or complete excision of in situ carcinoma confirmed by histology) during the 5 years prior to inclusion in this study.", "\u2022 History of major cardiovascular diseases, defined as follows:", "\u25cf Congestive heart failure is higher than that of the New York Heart Association (NYHA) Class II according to the NYHA Functional Classification.", "The unstable angina or myocardial infarction within 6 months of registration.", "A serious cardiac arrhythmia.", "A clinically significant electrocardiogram (ECG) abnormality, including an extended reference QT interval/ corrected QT interval ([QT/QTc], example, a repeated demonstration of a QTc interval > 500 milliseconds [ms]).", "A history of concomitant medical conditions or infectious diseases that, in the opinion of the investigator, would compromise the participant's ability to complete the study safely.", "\u2022 Hypersensitivity to the active substance or to any other excipient of the medicinal product eribulin mesylate, or severe hypersensitivity (>=Grade 3) to pembrolizumab and/or to any of its excipients.", "Intended for major surgery during the study.", "When diagnosed with immunodeficiency or receiving chronic systemic steroid therapy (as a dose greater than 10 mg per day of prednisone equivalent) or any other form of immunosuppressive treatment within 7 days of the first dose of the test treatment. The use of physiological doses of corticosteroids may be approved after consultation with the sponsor.", "He has a history of pneumonitis (non-infectious) requiring steroids or current pneumonitis.", "He has a history of interstitial pulmonary disease.", "Has an active infection requiring systemic treatment.", "Seasonal influenza vaccines that do not contain live viruses are allowed within 30 days of the start of the study.", "The investigator's belief that the participant is medically unfit to receive eribulin mesylate and pembrolizumab or otherwise unfit."], "Results": ["Performance measures:", "Objective response rate (ORR)", "The two-sided 95% confidence interval (CI) calculated using the Clopper-Pearson method. As expected, data up to the primary completion date were analysed only from the primary completion date.", "Delay: From the date of the first dose of the drug under study to the date of the first documentation of disease progression or death, whichever is the earlier (up to 3 years and 11 months)", "Results 1:", "Title of the arm/group: Strata 1: Eribilin Mesylate + Pembolizumab", "Arm/Group Description: Participants with mTNCB who were never treated with systemic anticancer therapy in metastatic media received 1.4 mg/m^2, intravenous infusion on days 1 and 8 and pembrolizumab 200 mg, intravenous infusion on day 1 in treatment cycle 1 (Safety Trial, Phase 1b) and then continued in each 21-day treatment cycle in the presence of clinical benefit until disease progression was confirmed, unacceptable toxicity development, participant request, withdrawal of consent or cessation of the study by the sponsor in phase 2 of stratum 1.", "Total number of participants analysed: 66", "Type of measurement: Number", "Unit of measure: percentage of participants 25.8 (15.8 to 38.0)", "Results 2:", "Title of arm/group: Stratum 2: Eribilin Mesylate + Pembolizumab", "Arm/group description: Participants with mTNCB previously treated with 1 to 2 systemic anticancer lines in the metastatic context received 1.4 mg/m^2, 1 intravenous infusion on days 1 and 8 and 2 pembrolizumab 200 mg, 1 intravenous infusion on day 1 in treatment cycle 1 (Safety Trial, Phase 1b) and then continued in each 21-day treatment cycle in the presence of clinical benefit until disease progression was confirmed, unacceptable toxicity development, participant request, withdrawal of consent or cessation of the study by the sponsor in phase 2 of stratum 2.", "Total number of participants analysed: 101", "Type of measurement: Number", "Unit of measure: percentage of participants 21.8 (14.2-31.1)"], "Adverse Events": ["Undesirable Events 1:", "Total: 30/66 (45.45 per cent)", "Anemia 1/66 (1.52%)", "Febrile neutropenia 1/66 (1.52%)", "Neutropenia 2/66 (3.03%)", "Cardiac arrest 1/66 (1.52%)", "Pericardial infusion 0/66 (0.00 %)", "\u2022 Adrenal impairment 1/66 (1.52%)", "Retinal Detachment 0/66 (0.00 %)", "Upper abdominal pain 1/66 (1.52%)", "- Collision 1/66 (1.52%)", "Constipation 0/66 (0.00 %)", "Diarrhoea 1/66 (1.52%)", "- Dual Ulcer 0/66 (0.00 %)", "Adverse Events 2:", "Total: 57/101 (56.44 per cent)", "Anemia 1/101 (0.99%)", "- Febrile neutropenia 3/101 (2.97 %)", "Neutropenia 3/101 (2.97%)", "Cardiac arrest 0/101 (0.00 %)", "1/101 (0.99%)", "\u2022 Adrenal impairment 1/101 (0.99%)", "Retinal Detachment 1/101 (0.99%)", "Upper abdominal pain 0/101 (0.00 %)", "- Collision 1/101 (0.99%)", "Constipation 1/101 (0.99%)", "Diarrhoea 0/101 (0.00 %)"]}